Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - granisetron hydrochloride - solution for injection - 1 milligram(s)/millilitre - serotonin (5ht3) antagonists; granisetron

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - granisetron hydrochloride - film-coated tablet - 1 milligram(s) - serotonin (5ht3) antagonists; granisetron

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - granisetron hydrochloride - film-coated tablet - 2 milligram(s) - serotonin (5ht3) antagonists; granisetron

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - granisetron hydrochloride - solution for injection - 3 milligram(s)/millilitre - serotonin (5ht3) antagonists; granisetron

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - naproxen - gastro-resistant tablet - 250 milligram(s) - propionic acid derivatives; naproxen

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - naproxen - gastro-resistant tablet - 500 milligram(s) - propionic acid derivatives; naproxen

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ibandronate sodium, quantity: 1.125 mg/ml (equivalent: ibandronic acid, qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - indicated for the treatment of: tumor-induced hypercalcaemia with or without metastases. metastatic bone disease in patients with breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; citric acid monohydrate; sodium chloride; water for injections; sodium hydroxide - adults: kytril (tablets and injection) is indicated for use in adults for: the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric: kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy..

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen sodium, quantity: 550 mg - tablet, film coated - excipient ingredients: purified water; microcrystalline cellulose; povidone; magnesium stearate; purified talc; titanium dioxide; hypromellose; macrogol 8000; indigo carmine - crysanal is indicated as an analgesic in acute migraine attacks, for the treatment of gout, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and for the relief of acute and/or chronic pain states in which there is an inflammatory component.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen sodium, quantity: 550 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; purified water; purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; indigo carmine - anaprox is indicated as an analgesic in acute migraine attacks, for the treatment of gout, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and for the relief of acute and/or chronic pain states in which there is an inflammatory component.